Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vanda Pharma (VNDA) Buy Rating and $15 PT Reiterated - Jefferies
May 5, 2016 9:45 AM EDTJefferies analyst, Chris Howerton, maintained his Buy rating and $15 PT after Vanda (NASDAQ: VNDA) reported a strong 1Q with 3 takeaways:
1) Hetlioz - strong 1Q sales (~$16.2M vs Jef est. of ~$15.4M) suggt'ng ~80 net patient adds in our model; EU launch in 3Q16 mgmt... More
